Ittrio (90y) Citrato Curium Italy

Yttrium-90 citrate, the active ingredient in Ittrio, is a radiopharmaceutical presented as an injectable solution for intra‑articular use. It is used to treat inflamed synovial tissue in conditions such as rheumatoid arthritis, hemophilic arthropathy and other inflammatory joint diseases, delivering localized beta radiation to the joint.

GNH USA supplies Ittrio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and specialty centers worldwide.

Ittrio is a radiosynovectomy agent that targets inflamed synovial membranes in various joint disorders. - Rheumatoid arthritis: reduces synovial inflammation and pain, improving joint mobility. - Hemophilic arthropathy: diminishes recurrent joint bleeding and synovial hypertrophy. - Other inflammatory joint diseases requiring radiosynovectomy: provides localized synovial ablation to control chronic inflammation.

Adverse reactions are generally related to the local radiation effect and injection procedure.

Common Side Effects: - Joint pain or discomfort at the injection site. - Swelling or effusion of the treated joint. - Warmth or mild erythema around the injection area. - Transient low‑grade fever. - Temporary increase in joint stiffness. - Minor bruising or hematoma.

Serious or Rare Side Effects: - Radiation‑induced cartilage damage leading to joint degeneration. - Severe joint infection (septic arthritis). - Allergic reaction to the citrate carrier. - Systemic radiation exposure causing hematologic abnormalities. - Development of secondary malignancy in the treated joint (very rare).

Prior to administration, clinicians should assess patient suitability and follow radiation safety guidelines. - Patient selection: avoid in joints with active infection or severe osteoarthritis. - Pregnancy and lactation: contraindicated unless benefits clearly outweigh potential fetal or infant risk. - Bleeding disorders: evaluate risk of hemarthrosis before intra‑articular injection. - Concomitant immunosuppressive therapy: monitor for delayed wound healing. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Yttrium-90 citrate may interact with other therapies that affect radiation exposure or joint health.

Major Interactions (Avoid): - Concurrent intra‑articular radioisotope therapy: cumulative radiation dose may exceed safety limits. - Systemic Yttrium-90 therapy: overlapping radiation exposure can increase toxicity.

Moderate Interactions (Monitor Closely): - Disease‑modifying antirheumatic drugs (e.g., methotrexate, biologics): may alter joint healing response. - Anticoagulants or antiplatelet agents: increased risk of joint bleeding post‑injection. - Corticosteroid intra‑articular injections: may affect distribution of the radiopharmaceutical.